Evidence map›Paper›PMID 38747382›Full record

ArticleProtein science : a publication of the Protein Society2024

Characterization of a novel format scFv×VHH single-chain biparatopic antibody against metal binding protein MtsA.

Risa Asano, Miyu Takeuchi, Makoto Nakakido, Sho Ito, Chihiro Aikawa, Takeshi Yokoyama, Akinobu Senoo, Go Ueno, Satoru Nagatoishi, Yoshikazu Tanaka and 2 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Risa AsanoDepartment of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID 0009-0007-7122-1221
Miyu TakeuchiDepartment of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.
Makoto NakakidoDepartment of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0328-9914
Sho ItoRigaku Corporation ROD Single Crystal Analysis Group Application Laboratories, Tokyo, Japan.
Chihiro AikawaSection of Applied Veterinary Sciences, Division of Veterinary Sciences, Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
Takeshi YokoyamaGraduate School of Life Sciences, Tohoku University, Miyagi, Japan.
Akinobu SenooDepartment of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-6911-360X
Go UenoRIKEN SPring-8 Center, Hyogo, Japan.
Satoru NagatoishiMedical Device Development and Regulation Research Center, School of Engineering, The University of Tokyo, Tokyo, Japan.
Yoshikazu TanakaGraduate School of Life Sciences, Tohoku University, Miyagi, Japan.
Ichiro NakagawaDepartment of Microbiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kouhei TsumotoDepartment of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development 19am0401010Japan Agency for Medical Research and Development 20mk0101170Japan Agency for Medical Research and Development JP18ak0101100Japan Science and Technology Agency JP MJCR20H8Japan Science and Technology Agency JP MJMI21G6Japan Society for the Promotion of Science 19H05766Japan Society for the Promotion of Science 20H02531Japan Society for the Promotion of Science 21H05090
6 · The paper itself

Abstract

Biparatopic antibodies (bpAbs) are engineered antibodies that bind to multiple different epitopes within the same antigens. bpAbs comprise diverse formats, including fragment-based formats, and choosing the appropriate molecular format for a desired function against a target molecule is a challenging task. Moreover, optimizing the design of constructs requires selecting appropriate antibody modalities and adjusting linker length for individual bpAbs. Therefore, it is crucial to understand the characteristics of bpAbs at the molecular level. In this study, we first obtained single-chain variable fragments and camelid heavy-chain variable domains targeting distinct epitopes of the metal binding protein MtsA and then developed a novel format single-chain bpAb connecting these fragment antibodies with various linkers. The physicochemical properties, binding activities, complex formation states with antigen, and functions of the bpAb were analyzed using multiple approaches. Notably, we found that the assembly state of the complexes was controlled by a linker and that longer linkers tended to form more compact complexes. These observations provide detailed molecular information that should be considered in the design of bpAbs.

Indexed as

Single-Chain AntibodiesAnimalsEpitopesHumansImmunoglobulin Heavy ChainsProtein EngineeringEpitopesImmunoglobulin Heavy ChainsSingle-Chain Antibodiesbiparatopic antibodycomplex formationinteractionmetal bindingnanobodyphysicochemical analysisprotein engineeringscFvVHH

Identifiers

PMID38747382
PMCPMC11094767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.